A Study of LY4060874 in Healthy Participants

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

132

Participants

Timeline

Start Date

December 2, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Healthy Participants

Interventions

DRUG

LY4060874

Administered SC

DRUG

LY4060874

Administered IV

DRUG

Placebo

Administered SC

DRUG

Placebo

Administered IV

Trial Locations (2)

Fortrea, Inc., Dallas

Lilly Centre for Clinical Pharmacology, Singapore

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY

NCT06709820 - A Study of LY4060874 in Healthy Participants | Biotech Hunter | Biotech Hunter